REVIEW ARTICLE
The elimination of Chagas' disease from Brazil

E. MASSAD*

School of Medicine, The University of São Paulo, LIM 01/HCFMUSP, Brazil, and London School of Hygiene and Tropical Medicine, London, UK

SUMMARY

On 9 June 2006 the Pan American Health Organization (PAHO) presented the Minister of Health of Brazil with the International Elimination of Transmission of Chagas' Disease Certificate. This act was the culmination of an intensive process that began in 1991 with the Southern Cone Initiative, a joint agreement between the governments of Argentina, Bolivia, Brazil, Chile, Paraguay, Uruguay and Peru, to control Chagas' disease by the elimination of the main vector, *Triatoma infestans*. This initiative has been highly successful and the prevalence area of the vector diminished rapidly in the last years. As a consequence, the current seroprevalence in children aged between 0 and 5 years is of the order of 10^{-5}, a clear indication that transmission, if it is occurring, is only accidental. In this review I calculate the basic reproduction number, R_0, for Chagas' disease and demonstrate that its relatively low value (1·25) explains why vectorial transmission was interrupted relatively easily. In addition, I used a mathematical model to forecast how long the remaining cases of the disease, as well as the additional vertically transmitted cases will last.

INTRODUCTION

In early 1909 a young and unknown Brazilian physician-cum-protozoologist, Carlos Ribeiro Justiniano das Chagas (1879–1934), was sent to investigate an outbreak of malaria that was disrupting the construction of an important railway in the state of Minas Gerais [1]. There he came across a new and strange disease, known to the locals as *baticum* (pronounced 'bah-tee-coom') [1], an onomatopoeic word for the palpitation resulting from the heart condition characteristic of the illness – American trypanosomiasis or Chagas' disease. The condition, first confounded with syphilis, caused cardiac insufficiency and a significant number of sudden deaths.

Chagas was pondering the causes of that strange disease and how it was transmitted when one of the railway engineers, drew his attention to the large number of triatomine bugs in the area. These were known locally as *barbeiro* (barber) due to their habit of biting humans on the face [1]. When Chagas examined the intestines of the bugs he found the trypomastigote forms of trypanosomes, the causal agent of American trypanosomiasis. Since Chagas was familiar with the characteristics of vector-borne tropical diseases such as malaria and yellow fever, the detection of a hitherto unknown trypanosome in the gut of a reduviid bug prompted him to search for a related vector-borne disease [2]. A few weeks after the discovery of the trypanosome in the bug he examined a baby girl, who had presented with a strange swelling of one eyelid, fever and malaise [3]. A drop of her blood revealed the same trypanosomes found in the bugs – the cycle was completed.

* Address for correspondence: Dr E. Massad, Rua Teodoro Sampaio 115, São Paulo, CEP 05405-000, SP, Brazil.
(Email: edmassad@usp.br)

With this first human case identified, Chagas completed an extraordinary cycle of work, without precedence in the history of medicine thus far: he discovered a new disease, identified its agent and its transmission mechanism within the space of a few weeks. Chagas was twice formally nominated for the Nobel Prize in 1913 and 1921 but was never awarded it.

Less than 100 years later Brazil became the first Latin American country to eliminate transmission of Chagas' disease by *Triatoma infestans*, its main vector in the country [3]. The Pan American Health Organization (PAHO) marked the milestone on 9 June 2006 by presenting the Minister of Health with an International Elimination of Transmission of Chagas' Disease Certificate. The achievement was confirmed by an international expert commission based on visits to every Brazilian state [4, 5].

In this review I have addressed the elimination of Chagas' disease transmission. Following a summary of the infection, emphasizing its transmission mechanism and its distribution in Brazil, I have discussed its main determinant of transmission. I then analysed the possible determinants of its elimination, the strategy used, the difficulties encountered, lessons learned, the future for world eradication of Chagas' disease, and what it means to the populations no longer affected.

I have also calculated the basic reproduction number, R_0, for Chagas' disease and demonstrated that its relatively low value (1·25) explains why vectorial transmission was interrupted fairly easily. In addition, I have used a mathematical model to forecast how long the remaining cases of the disease, as well as the additional vertically transmitted cases will last.

THE DISEASE

American trypanosomiasis (Chagas' disease) is a zoonosis caused by the protozoan parasite *Trypanosoma cruzi* (a homage to Oswaldo Cruz, the head of Carlos Chagas' department at the time of the discovery) [6]. The disease has two phases: acute and chronic.

Acute Chagas' disease [7] is usually an illness of children, but it can occur at any age [8]. The acute phase begins after an infected bug bites a susceptible human and defecates in the spot [9, 10]. Some hours later, the biting site produces a characteristic swelling called 'chagoma' [11]. Unilateral orbital oedema, lymphangitis and satellite ganglia engorgement, the

so-called Romaña sign, should always suggest acute Chagas' disease in an endemic area [11]. Fever and tachycardia develop. An ECG may show alterations in ventricular repolarization, subepicardic ischaemia and first-degree atrioventricular block [11]. Acute phase infection is not usually fatal and often passes unperceived. After a few weeks the disease settles into the more chronic phase. The clinical manifestations of chronic Chagas' disease, however, appear decades after the acute phase. Cardiomyopathy, the commonest manifestation, is characterized by extrasystoles (hence the name *baticum*) and various degrees of atrioventricular block. Valvular incompetence is also a common feature and is caused by the characteristic cardiac dilatation, which sometimes evolves to apical aneurysm [11]. Sudden death due to ventricular fibrillation [12] and as a result of autonomic cardiac dysfunction [13] is frequently recorded.

Other chronic manifestations of Chagas' disease are the so-called megasyndromes [11], in particular megaoesophagus and megacolon [14]. The former is characterized by a progressive difficulty in swallowing and the latter by chronic constipation.

Congenital transmission may occur at any time of pregnancy, in successive gestations and may affect twins. The infection may produce pathology in the growing foetus. The consequences for the newborn are variable, ranging from asymptomatic to severe clinical manifestations. Congenital transmission cannot be prevented, but early diagnosis of the newborn enables prompt treatment, achieving cure rates close to 100 % (the treatment regimen should include benznidazol between 5 and 10 mg/kg per day for 30–60 days or nifurtimox at 10–15 mg/kg per day for 60 days), thus avoiding progression to chronic Chagas' disease. It is a consensus that congenital Chagas' disease will be a pressing public health concern until the pool of infected women of childbearing age decreases to insignificant levels, which may only happen 30 years hence.

Transmission

The principal mechanism of Chagas' disease transmission is by the bite of insect vectors called triatomine bugs [15]. These blood-sucking bugs become infected by biting an infected animal or person. The vector belongs to the subfamily Triatominae (Hemiptera: Reduviidae) [16–18] comprising 130 recognized species, of which about a dozen can transmit the trypanosome.

The bugs are found in houses made from materials such as mud, adobe, straw, and palm thatch. During the day, the bugs hide in crevices in the walls and roofs. During the night, when the inhabitants are sleeping, the bugs emerge. Because they tend to feed on people's faces, triatomine bugs are also known as 'kissing bugs'. Infected bugs pass *T. cruzi* in their faeces.

After they bite and ingest blood, they defecate. The person becomes infected if *T. cruzi* parasites in the bug faeces enter the body through mucous membranes or breaks in the skin. The unsuspecting, sleeping person may accidentally scratch or rub the faeces into the bite wound, eyes, or mouth.

Other forms of transmission include: consumption of uncooked food contaminated with faeces from infected bugs; congenital transmission (from a pregnant woman to her baby); blood transfusion; organ transplantation; and accidental laboratory exposure [15].

Chagas' disease is not transmitted from person-to-person.

Chagas' disease distribution in Brazil before the intervention programme

The disease, which probably had its origins in Brazil, is limited to the Western Hemisphere. Most reported cases occurred in Brazil, Argentina, Chile and Venezuela [19]. Cases have also been reported in Peru, Mexico and other Central and South American countries.

Trypanosoma cruzi, the causal agent of Chagas' disease, is found exclusively in the Americas. It is a member of the class Mastigophora, family Trypanisomidae and has over 100 vertebrate hosts, including dogs, cats armadillos, opossums, monkeys, and humans [19]. It is present in all habitats of its triatomine vectors, between latitudes 41° N and 46° S [9, 20]. It is estimated that, in the 1980s, about 80 million people lived in areas with risk of transmission [21, 22].

The endemic area in Brazil, not surprisingly, coincides with the geographical distribution of *Triatoma infestans*, its main vector (Fig. 1), and comprises 2 million km², a quarter of the national area. In 1980 there were 120 000 new cases. In the period between 1975 and 1978 the Ministry of Health of Brazil carried out a seroprevalence survey in the endemic area and found 4·1 % individuals positive, equivalent to about 800 000 cases of the disease [9].

Fig. 1. Geographical distribution of *Triatoma infestans* in South America (from [23]).

Of historical interest is the case of Charles Darwin, who wrote that he was bitten by a huge *Triatoma* while in South America [19]. According to Burnet [24] Darwin's mysterious chronic illness, from which he suffered, dated from this time, and he cited a distinguished protozoologist who believed that Darwin was infected with Chagas' disease.

Chagas' disease as a vector-borne infection

Between 1877 and 1910 eleven different infections including Chagas' disease were shown to require a blood-sucking arthropod vector for transmission to humans [25, 26]. Most of the techniques used for control and eradication of those vector-borne diseases were developed in the early 20th century. Reduction of vectors' breeding places, insecticides, biological control, vaccination, chemotherapy and personal protection were established nearly a century ago [10]. Many of those techniques are still effective; others succeeded initially but failed to achieve eradication later for a variety of reasons. Investigators must now incorporate new approaches that will allow them to move to the next level of control to alleviate the effects of vector-borne diseases on human and animal health [10].

The rest of this section is crucial for explaining why Chagas' disease transmission was eliminated from Brazil. The equations given are important for

understanding the causes of the interruption of transmission.

The central parameter related to the intensity of transmission of infections is the so-called basic reproduction number (R_0), defined by Macdonald [27, 28] as the number of secondary human infections produced by a single infective in an entirely susceptible population. Originally applied in the context of malaria, R_0 is a function of the vector population density as related to the host population, m, the average daily biting rate of the vector, a, the host susceptibility, b, the vector susceptibility, c, the vector mortality rate, μ, the parasite extrinsic incubation period in days, n, and the parasitaemia recovery rate, r, resulting in the famous equation:

$$R_0 = \frac{mabc \exp(-\mu n)}{\mu r},$$ (1)

where $\exp(-\mu n)$ is the fraction of the infected vector population that survives through the extrinsic incubation period n of the parasite.

From the definition of the basic reproduction number it is clear that if R_0 is <1, the disease dies out. Hence, in the original Macdonald analysis, R_0 coincides with the threshold for infection persistence, i.e. $R_0 = 1$.

In his seminal paper, Macdonald [27] addressed the problem of a system involving one vector (*Anopheles* mosquitoes) and one host (man). As mentioned above, his definition of R_0 is the number of secondary infections produced by a single infected person along one entire infectious period. I shall deduce an explicit expression for R_0 from an intuitive perspective to show that it coincides with the threshold for the establishment of the disease.

Let us begin by assuming that the index case is a human host. The question to be answered is how many human secondary infections this index case produces in one entire infectious period.

Let N_m be the number of arthropod vectors and a the average daily biting rate vectors inflict on the human population. The number of bites in the human population per day is, therefore, $N_m a$. Let N_h be the number of humans and r the rate of recovery from parasitaemia in the human cases. Therefore, the index case produces

$$\frac{N_m a}{N_h r} c_{h \to m}$$ (2)

infected vectors, where $c_{h \to m}$ is the probability that a vector becomes infected after biting an infective

human. Those $(N_m a / N_h r) c_{h \to m}$ infected vectors, in turn, produce

$$a \frac{N_m a}{N_h r} c_{h \to m} \frac{1}{\mu} b_{m \to h} \exp(-\mu n)$$ (3)

new human cases in the first generation, where (l/μ) is the average life expectancy of mosquitoes, $b_{m \to h}$ is the probability that a human gets the infection after being bitten by an infective mosquito and $\exp(-\mu n)$ is the fraction of the infected vector population that survives through the extrinsic incubation period n of the parasite. Note that once infective, a vector is assumed to remain so for life. Therefore, the expression for R_0 is [29]:

$$R_0 = a \frac{N_m a}{N_h r} c_{h \to m} \frac{1}{\mu} b_{m \to h} \exp(-\mu n),$$ (4)

which is just another way of writing equation (1).

A simple sensitivity analysis shows to which of its components R_0 is most sensitive [30–35]. This can be done by taking the partial derivative of equation (4) with respect to each of the parameters. Each of these partial derivatives represents one control strategy. So, for instance, to estimate the impact of bed nets on the value of R_0 we take the derivative with respect to the biting rate, a, because bed nets reduce the contact between the vector and the human host. The result is:

$$\frac{\partial R_0}{\partial a} = 2 \frac{N_m a}{N_h r} c_{h \to m} \frac{1}{\mu} b_{m \to h} \exp(-\mu n).$$ (5)

Another way to reduce the contact between vectors and human hosts is the use of repellents in infected people. This would, in a sense, protect the vector (like bed nets) and, therefore, the partial derivative would be with respect to the product ac, i.e.

$$\frac{\partial R_0}{\partial ac_{h \to m}} = \frac{N_m a}{N_h r} \frac{1}{\mu} b_{m \to h} \exp(-\mu n).$$ (6)

Improving housing conditions would reduce the breeding places for *Triatoma* vectors and this, in turn, would reduce the number of adult vectors N_m and the partial derivative should be with respect to this variable:

$$\frac{\partial R_0}{\partial N_m} = \frac{a^2}{N_h r} c_{h \to m} \frac{1}{\mu} b_{m \to h} \exp(-\mu n).$$ (7)

Treatment of infected people would increase the recovery rate from parasitaemia, r. Hence we have:

$$\frac{\partial R_0}{\partial r} = -a^2 \frac{N_m}{N_h} c_{h \to m} \frac{1}{\mu} b_{m \to h} \exp(-\mu n) \frac{1}{r^2}.$$ (8)

Fig. 2. Impact of a control strategy on the value of R_0.

Finally, the use of insecticides has the effect of increasing the vector mortality rate, i.e. the parameter μ. The sensitivity equation is now:

$$\frac{\partial R_0}{\partial \mu} = -n\frac{N_m a}{N_h r}\frac{1}{\mu}b_{m\to h}c_{h\to m}\exp(-\mu n)$$
$$-\frac{N_m a}{N_h r}\frac{1}{\mu^2}b_{m\to h}c_{h\to m}\exp(-\mu n). \quad (9)$$

Numerically, the parameter to which R_0 is most sensitive is the vector mortality rate.

Another important aspect of R_0 is its relationship with the prevalence level of human disease at equilibrium [36], P:

$$P = 1 - \frac{1}{R_0}. \quad (10)$$

Considering that the prevalence of Chagas' disease at equilibrium before the beginning of the intervention programme in the endemic regions was 16 million infected people in an 80 million population at risk [37] we can calculate the value of R_0 in this area, which is 1·25.

Let us now assume a control strategy of spraying insecticides regularly in the affected areas. This strategy leads to an increase in the vectors' mortality rates. The impact of such a strategy can be simulated, beginning at the equilibrium value of R_0 estimated as 1·25 for the affected areas in Brazil and the result can be seen in Figure 2.

Note that an increase of only 25 % in the basal mortality rate of the vector is enough to reduce the value of R_0 below the critical threshold of 1, thus making the disease disappear from this area. As discussed below this is the main explanation for the success of the elimination programme against vectorial transmission of Chagas' disease.

The control strategies

The strategy to control Chagas' disease consisted essentially of interrupting transmission by domestic vector control and ensuring safer blood transfusion.

Fig. 3. *Triatoma infestans* and its life cycle in the wall of a typical house in the endemic area. (1) Eggs, (2) first-stage nymphs, (3) fifth-stage nymph, (4) adult (from [39]).

Chagas recognized the importance of improving living conditions to control the vector [38]. He noticed that bugs lived in cracks and crevices in the house walls, made by bamboo sticks and mud (Fig. 3) and realized that improved buildings would reduce the breeding and hiding places for the bugs.

Since improving housing conditions is an expensive strategy and was applied only in restricted cases [40] insecticide spraying became the most widely used control measure. The efficacy of systematic fogging with insecticides since the first developments of gamma-hexachlorocyclohexane (BHC) in 1947 [41] recommended its use as the first control alternative [40]. The possibility of controlling domestic triatomine vectors with a variant of that new insecticide was demonstrated in the following year [42]. This triggered the first National Campaign against Chagas' disease in 1950 [40] by the National Service of Malaria. For many years BHC remained the mainstay of Chagas' disease vector control trials and campaigns, although dieldrin was widely used in other countries, e.g. Venezuela [38]. Until the advent of synthetic pyrethroid insecticides in the early 1980s, several classes of insecticides were trialled against triatomine vectors, but none showed the efficacy and copst-effectiveness of BHC and dieldrin.

In 1983 the first Brazilian national campaign was launched and by 1986 75 % of the initial objectives

had been attained, in the sense that infested localities had been mapped, sprayed, and placed under community-based surveillance [38]. Unfortunately, by that epoch dengue re-emerged in Brazil and the almost complete mobilization of the Brazilian public health systems towards dengue control placed the Chagas' disease campaign subordinate to a new urban *Aedes aegypti* campaign.

In 1991, the Southern Cone Initiative, a joint agreement between the governments of Argentina, Bolivia, Brazil, Chile, Paraguay, Uruguay and Peru, to control Chagas' disease by the elimination of the main vector, *Triatoma infestans* was signed. This initiative has been highly successful and the prevalence of the vector plummeted in the last years [43].

This programme consisted of three operational phases [20]:

(1) preparatory phase for mapping and general programming of activities and estimation of resources;
(2) attack phase during which a first massive insecticide spraying of houses followed by a second spraying 2–3 months later, with additional evaluations for selective spraying of re-infected houses; and
(3) surveillance phase for the detection of residual foci of triatomines after the objective of the attack phase has been reached.

The primary objective of the Southern Cone Initiative was the elimination of *T. infestans*, including suppressing or controlling populations of other species that might be of local importance. The second objective was to reduce the risk of Chagas' disease transmission by blood transfusion. Transfusional Chagas' disease was suspected in early 1940 and definitively defined in the 1940s [38], although the tools to control it were only developed 10 years later [38, 44]. However, it was only with the emergence of HIV/AIDS in 1980s that national programmes of blood control were fully implemented [44–46]. The strategy to control transfusional Chagas' disease consisted in blood screening by serological test and chemoprophylaxis of suspected blood with trypanocidal drugs [37, 44].

Vertical transmission, the third most important way of acquiring Chagas' disease, was known since the 1940s [38]. Although the estimated probability of transplacental transmission of *T. cruzi* varies considerably, it may reach 10% [37, 47]. Control has been restricted to early diagnosis and specific treatment of infected newborns [38].

Difficulties encountered

The first difficulty encountered with controlling Chagas' disease by attacking the vector was the cost of the proposal to improve housing conditions. At the time of Chagas' discovery in 1909, Brazil had about 24 million inhabitants [48], of whom 5 million were at risk of acquiring the infection [assuming $R_0 \cong 1 \cdot 25$; see equation (9)]. This implied improving about 1 million dwellings. The cost of restoring each house to control triatomine breeding conditions was estimated at between US$500 and US$1000 in present-day US$, making a total cost between US$0.5 and US$1 billion. Considering that the gross national product (GNP) of Brazil at that time was US$7.2 billion [49] (in 1999 US$), between 7% and 14% of the GNP would be needed to control the infection by improving housing conditions. This was an unattainable task.

The second difficulty concerned the use of synthetic insecticides, developed in 1940s, for vector control. DDT, the cheapest and widely applied insecticide, was ineffective against the main vector *Triatoma infestans* [38]. Two new organochlorines were developed, dieldrin and BHC, which were shown to be very effective when sprayed over house walls [50]. As previously mentioned, BHC was replaced in the 1980s by synthetic pyrethroid insecticides. These were considerably more expensive than BHC, but because they could be used in low doses, their ease of use, infrequent application and lack of unpleasant smell [38], they proved to be cost-effective and advantageous. House spraying with synthetic pyrethroid became the standard strategy against Chagas' disease. The main difficulty, however, faced by this strategy was the re-emergence of dengue in 1986. This vector-borne infection drew all the attention of the Brazilian Public Health authorities at that time. Diversion of resources toward *A. aegypti* is still common up to present days. About 90% of the budget of the Centre of Zoonosis Control (CZC) was directed to dengue control, the remaining 10% for rabies control.

Further difficulty was that the resources applied in the vectorial control of Chagas' disease were left over from the malaria control programme, malaria having been eradicated from triatomine-endemic areas [51]. This fact compromised the planning of control actions that should be strictly based on epidemiological

criteria based on information derived from entomo-logical and serological screenings carried out at the time.

All these above difficulties were eventually over-come and vector control has remained the main strategy against the disease. The combination of a relatively low value of R_0 associated with persistent house spraying with insecticides proved to be highly effective against triatomine vectors and the result is the certification of transmission elimination Brazil managed to obtain.

Pre-transfusional serodiagnosis, the main strategy to control transfusional Chagas' disease also pre-sented some difficulties. The first problem was the lack of legal instruments and regulations that could enforce donor selection. The regulations date from the 1980s [45]. As late as 1995, only three of the six South Cone Initiative countries had a specific law controlling blood donation [52]. In addition, oper-ational difficulties related to the first screening test applied (complement fixation) were only overcome with the advent of new techniques like immuno-fluorescence, indirect haemmaglutination and ELISA [53]. However, perhaps the greatest difficulty in con-trolling transfusional Chagas' disease was the huge migration flow of infected individuals from endemic areas to the great urban centres since the 1950s [54]. This resulted in the fact that in the 1970s, of the 100 000 new cases of Chagas' disease per year in Brazil, 20 000 were due to transfusion, of which 1500 new cases occurred in the city of São Paulo, a non-endemic area [55]. As mentioned earlier, the emerg-ence of HIV/AIDS improved the quality of blood screenings and transfusional transmission of *T. cruzi* ceased to be an important way of acquiring the in-fection in Brazil.

Congenital transmission of *T. cruzi* infection was also targeted. The success in the control of vector-transmitted Chagas' disease and screening pro-grammes in blood banks uncovered the public health relevance of congenital transmission, which has been gradually emerging in vector-free suburban areas and non-endemic cities [56]. The main difficulty in con-trolling it was due to the lack of an efficient pre-natal programme that could diagnose the infection in can-didate mothers coupled with a safe chemoprophylaxis to then reduce the likelihood of vertical transmission. This is the greatest challenge in eradicating Chagas' disease from Brazil since there still remain an esti-mated 8000–16000 new cases per year of congenital transmission [56]. Although congenital transmission

Fig. 4. Geographical distribution of *Triatoma infestans* in South America as a result of the control programme (from [23]).

cannot be prevented, early diagnosis enables prompt treatment of newborns achieving cure rates close to 100% [56].

The impact of Chagas' disease control

In Brazil the control programme has been operating since 1975. At that time 711 of the > 5000 munici-palities had triatomine-infested houses targeted by the programme [20]. In 1986, 186 cities remained infested and in 1993, 83 municipalities infested with tri-atomines were detected. The current geographical distribution of *T. infestans* in South America (Fig. 4) shows that, compared with the area displayed in Figure 1 of 6 278 081 km² [57], the current estimate is 913 485 km² [23]. This illustrates the impact of control strategies. Note that Brazil is free from *T. infestans*.

The effectiveness of the South Cone Initiative is measured using various parameters. The estimated burden of disease in terms of disability-adjusted life years (DALY) [58] declined from 2·7 million in 1990 [59] to 586 000 in 2001 [60]. From 1975 to 1995, the programme (excluding blood banks) prevented an estimated 89% of potential disease transmission, preventing 2 339 000 new infections and 337 000 deaths in the whole region [20].

Reports from Brazil in the late 1980s suggested that the aggregate cost for pacemakers and intestinal surgery for Chagas' disease was US$250 million

per year. This excludes the costs of consultations, care, and supportive treatment for chronic chagasic patients, which amounted to US$1000 per year per patient, and disability awards, which in one state accounted for US$399 600 [61, 62]. In contrast, the annual investment cost was estimated as US$300 000 [23]. In addition, cost-effectiveness analysis demonstrated that for each US$39 spent on the programme 1 DALY was gained.

The significant reductions in the percentage of houses infested with triatomines were accompanied by a rapid reduction in the frequency of acute cases [63, 64]. In addition, vector control was also associated with important reduction in transmission by secondary mechanisms such as transfusional and congenital transmission. Therefore, the prevalence of the infection in the 0–4 years age group was reduced from 5% in 1980 [65] to 0·12% in 2000 [66], an impact of 98%.

Another important aspect of transmission interruption is the impact on the clinical features of chronic infections. There was a significant reduction in morbidity and premature mortality, suggesting an indirect benefit due to the absence of re-infection. Previous studies in the 1960s [67] and 1970s [68] already suggested that a reduction of re-infection, due to reductions in vector infestations, might be responsible for the declining morbidity in chronically infected individuals.

As previously mentioned, following the emergence of HIV/AIDS, strict control of blood banks helped to dramatically reduce the number of transfusional cases of Chagas' disease. Almost all Latin American endemic countries now have legislation regulating the screening of blood for transfusion [69]. This control, linked to vector control, is contributing to a progressive reduction in the number of people acquiring the infection by blood transfusion [44].

Finally, serological screening of children born to chagasic mothers 6 months after birth (serology performed before 6 months could reflect transplacental antibodies), with immediate treatment of those positive is reducing the number of vertically transmitted cases of Chagas' disease. This strategy, associated with vector control, is expected to have an important impact in reducing congenital transmission because the important reduction in re-infection reduces the likelihood of transmission to women of childbearing age [38], and there are preliminary indications suggestive of a decline in the vertical transmission due to this lack of re-infection [70].

Fig. 5. Age distribution of half-life of number of cases in each age group.

The future

Presently there are about 3·5 million people living with Chagas' disease in Brazil [21]. It would be very convenient to have an estimate of the time when the disease can be considered as eradicated, i.e. when there is no individual living with the disease. For this, it is necessary to project the current number of individuals considering age-dependent prevalence and mortality rates. By applying simple demographic models we can estimate how long it will take for the disease to disappear from the country, considering the current status of no vector and transfusional transmission and the residual congenital transmission.

If we assume the estimated age distribution of Chagas' disease prevalence [71] and mortality rate [72] we can calculate, with demographic models [73], the half-life of each age group. The result can be seen in Figure 5.

It can be seen in the figure that the 15–29 years age group, for instance, has a half-life of 30 years. This implies that, from the current 480 000 estimated cases in this age group, 240 000 will still be alive in 30 years time. Moreover, from the current 227 500 estimated cases for the 0–4 years age group, in 40 years there will be 113 750 individuals alive, and so on. Therefore, even if the transmission were completely interrupted now, it would take several decades before complete eradication of cases.

It is possible, with the use of a simple mathematical model (described in the Appendix) to forecast [74] the total number of Chagas' disease cases from vertical transmission. Therefore, assuming that from the currently estimated 2·5 million cases of Chagas' disease, 51% or 1·785 million are women. Assuming also the estimated age distribution of Chagas' disease prevalence [71] and mortality rate [72], and the age

Fig. 6. Forecast of Chagas' disease assuming infected mothers and congenitally infected children for the next 50 years. The proportion of treated children is 0% (upper curve), 20%, 40%, 60% and 80% (lowest curve).

distribution of female fertility [75] and general mortality rate for Brazil [76], we can estimate the time evolution of cases of congenital Chagas' disease. The result of the simulation of the model described in the Appendix, assuming different proportions of treated children can be seen in Figure 6.

Note that, beginning with the currently estimated number of infected women in the reproductive age of 760 000 cases, there is a marked reduction in the total number of cases (the sum of infected mothers and children), which is not very sensitive to treatment. Note also that the number of cases will linger for several decades.

CONCLUSIONS

The successful elimination of vectorial and transfusional transmission of Chagas' disease is a result of the South Cone Initiative. Authorities managed to reduce domestic density of the primary vector *T. infestans* and to achieve almost 100% of coverage in blood serological selection. As previously mentioned, the basic reproductive number of Chagas' disease was close to 1, i.e. not far from the threshold. Therefore, an average reduction of 25% in the vector life expectancy (feasible thanks to the domestic habits of *T. infestans*) was enough to reduce R_0 below unity, and to achieve the elimination of this form of transmission. However, control cannot be relaxed. Other secondary vectors, like *T. brasiliensis* in Northeast Brazil show peridomestic habits and new methods to control such peridomestic populations are still needed.

From the five requirements for the existing programmes summarized in the literature [77–79], the first two: (1) to maintain the political priority of the programme until its consolidation (5–10 years), and (2) to improve and refine epidemiological surveillance, that must become more focused at peripheral administrative levels supported by regional and national technical reference groups, are practically fully attained in Brazil. There remain the other three, namely, (3) to improve and refine methods and strategies for the control of peridomestic infestation by secondary vector species; (4) to cover 100% of blood transfusion with prior serological selections; and (5) to improve medical and social attention to the remaining chagasic individuals'. Of these, the achievement of items (4) and (5) are well advanced and the main attention should be focused on the control of secondary vectors. In particular in the Amazon region, we have a worrying number of new cases of Chagas' disease, as well as evidence of progressive domestication of vector species such as *Panstrongylus geniculatus*, *Triatoma maculata* and *Rhodnius brethesi* [80].

But perhaps the greatest challenge to avoid recrudescence of Chagas' disease transmission in Brazil is the so-called 'curse of success' [23], whereby success in reducing the epidemiological burden invariably also reduces political interest and operational budgets [23]. The need for continued surveillance and intervention becomes less appreciated at the political level [38] and there is a dangerous tendency for political authorities to underestimate the potential resurgence of vectorial transmission and give priority to emergent infections, as occurred with dengue in the early 1980s. It should be borne in mind that although the reproductive number of Chagas' disease is currently below unity, there are more than 100 mammal species that harbour the parasite and negligence from the health authorities would be sufficient for it to return to its pre-control level. That would be a tragedy.

For an interesting historical account of R_0 see [28] and for a detailed account of R_0 for complex diseases see [29–35].

APPENDIX

This Appendix describes the dynamical model used for forecasting the total number of Chagas' disease cases for the next decades.

The model assumes a population divided into four states, namely, infected mothers, M, uninfected newborns, F, infected newborns, C, and treated and

recovered children, *R*. The dynamics of the model is explained by the following set of equations:

$$
\left.
\begin{aligned}
\frac{dM(a)}{da} &= -\mu_M(a)M(a) - (1-p)r_M M(a) \\
&\quad - p r_M M(a) \\
\frac{dF(a)}{da} &= (1-p)r_M M(a) - \mu_F(a)F(a) \\
\frac{dC(a)}{da} &= p r_M M(a) - (\mu_C(a) + \delta(a))C(a) \\
\frac{dR(a)}{da} &= \delta(a)C(a) - \mu_R(a)R(a) \\
N_T(a) &= M(a) + C(a)
\end{aligned}
\right\}
\quad (A1)
$$

where *a* stands for age and the definition of the parameter and their values are detailed in Table A1.

Table A1. *Parameter definitions and values used in the model (A1)*

Parameter	Definition	Value
$\mu_M(a)$	Mother's mortality rate	$0{\cdot}0111\exp(0{\cdot}025a)$ [75]
$r_M(a)$	Mother' fertility rate	$\theta(49-a)0{\cdot}02$*
$\mu_F(a)$	Uninfected children's mortality rate	$0{\cdot}0111\exp(0{\cdot}025a)$ [75]
p	Infection proportion	$0{\cdot}1$ [37]
$\mu_C(a)$	Infected children's mortality rate	$0{\cdot}0143\exp(0{\cdot}0252a)$
$\delta(a)$	Treatment rate	Variable
$\mu_R(a)$	Recovered children's mortality rate	$0{\cdot}0111\exp(0{\cdot}025a)$ [75]

* The Heaviside θ-function [81] (a step function that is equal to 0 when the argument is <0, and 1 when the argument is $\geqslant0$) was used in order to guarantee that women reproduced at a rate of 2% per year up to age 49, ceasing to do so from then onwards.

ACKNOWLEDGEMENTS

DECLARATION OF INTEREST

None.

REFERENCES

1. **Scliar M.** *Oswaldo Cruz and Carlos Chagas: the Birth of Science in Brazil* [in Portuguese]. São Paulo: Odysseus, 2002.
2. **Perleth M.** The discovery of Chagas' disease and the formation of the early Chagas disease concept. *History and Philosophy of the Life Sciences* 1997; **19**: 211–236.
3. **Punukollu G, Gowda RM, Khan IA.** Early twentieth century descriptions of Chagas heart disease. *International Journal of Cardiology* 2004; **95**: 347–349.
4. **PAHO.** The Newsletter of the Pan American Health Organization (http://www.paho.org/English/DD/PIN/ptoday24_aug06.htm). Accessed 2 March 2007.
5. **Ministério de Saúde** (http://portal.saude.gov.br/portal/aplicacoes/busca/buscar.cfm). Accessed 2 March 2007.
6. **Kirchhoff LV.** American trypanosomiasis (Chagas' Disease). In: Guerrant RL, Walker DH, Weller PF, eds. *Tropical Infectious Diseases. Principles, Pathogens and Practice*. New York: Churchill Livingstone, 2000.
7. **Rassi A, Rassi Jr. A, Rassi GG.** Acute Chagas' disease [in Portuguese]. In: Brener Z, Andrade ZA, Barral-Neto M, eds. *Trypanosoma cruzi e Doença de Chagas*. Rio de Janeiro: Guanabara Koogan, 2000.
8. **Kirchhoff LV.** Trypanosoma species (American Trypanosomiasis, Chagas' Disease): Biology of Trypanosomes. In: Mandell GL, Bennet JE, Dolin R, eds. *Principles and Practice of Infectious Disease*. Philadelphia: Elsevier, Churchill Livingstone.
9. **Rey L.** *Parasitologia*, 3rd edn [in Portuguese]. Rio de Janeiro: Guanabara Koogan, 2001.
10. **Beaty B, Marquardt WC.** *The Biology of Disease Vectors*. Niwot: University Press of Colorado, 1996.
11. **Marsden PD.** American Trypanosomiasis. In: Cook GC, ed. *Manson's Tropical Diseases*, 20th edn. London: W. B. Saunders Company Ltd, 1996.
12. **Prata A, Lopes ER, Chapadeiro E.** Characteristics of non-expected sudden death in Chagas' disease [in Portuguese]. *Revista Brasileira de Medicina Tropical* 1986; **19**: 9–12.
13. **Junqueira LF.** On the possible role of autonomous cardiac dysfunction on sudden death associated with Chagas' disease [in Portuguese]. *Arquivos Brasileiros de Cardiologia* 1991; **56**: 420–434.
14. **Resende J.** Digestive manifestations [in Portuguese]. In: Brener Z, Andrade ZA, Barral-Neto M, eds. *Trypanosoma cruzi e Doença de Chagas*. Rio de Janeiro: Guanabara Koogan, 2000.
15. **CDC** (http://www.cdc.gov/ncidod/dpd/parasites/chagas_disease/factsht_chagas_disease.htm). Accessed 8 March 2007.
16. **Schofield CJ.** Biosystematics and evolution of the Triatominae. *Cadernos de Saúde Pública* 2000; **16** (Suppl. 2): 89–92.
17. **Lent H, Jurberg J, Galvão C.** Revalidation of genus *Mepraia* Mazza, Gajardo & Jorg, 1940 (Hemiptera Reduviidae) [in Portuguese]. *Memórias do Instituto Oswaldo Cruz* 1994; **89**: 347–352.
18. **Schofield CJ.** *Triatominae – Biology and Control*. West Sussex: Eurocomunica Publications, 1994.

19. **Allison MJ.** 1993. Chagas' Disease, chapter 25. In: Kiple KF, ed. *The Cambridge World History of Human Disease*. Cambridge: Cambridge University Press, 1993, pp. 636–638.

20. **Moncayo A.** Chagas disease: current epidemiological trends after the interruption of vectorial and transfusional transmission in the Southern Cone countries. *Memórias do Instituto Oswaldo Cruz* 2003; **98**: 577–591.

21. **Kropf SP, Azevedo N, Ferreira LO.** Biomedical research and public health in Brazil: the case of Chagas' Disease (1909–1950). *Journal of the Society for the Social History of Medicine* 2003; **16**: 111–129.

22. **WHO** (www.who.int/ctd/chagas). Accessed 2 March 2007.

23. **Schofield CJ, Jannin J, Salvatella R.** The future of Chagas disease control. *Trends in Parasitology* 2006; **22**: 583–588.

24. **Burnet FM.** *Natural History of Infectious Disease*, 3rd edn. Cambridge: Cambridge University Press, 1962.

25. **Philip CB, Rozenboom LE.** Medico-veterinary entomology: a generation of progress. In: Smith RF, Mitler TE, Smith CN, eds. *History of Entomology*, Palo Alto: Annual Reviews Inc., 1973.

26. **Gubler DJ.** Resurgent vector-borne diseases as a global health problem. *Emerging Infectious Diseases* 1998; **4**: 442–450.

27. **Macdonald, G.** The analysis of equilibrium in malaria. *Tropical Disease Bulletin* 1952; **49**: 813–828.

28. **Dietz, K.** The estimation of the basic reproduction number for infectious diseases. *Statistical Methods in Medicine* 1993; **2**: 23–41.

29. **Lopez LF, et al.** Threshold conditions for infection persistence in complex host-vectors interactions. *Comptes Rendus Biologies Académie des Sciences Paris* 2002; **325**: 1073–1084.

30. **Burattini MN, et al.** Modelling the control strategies against dengue in Singapore. *Epidemiology and Infection*. Published online: 31 May 2007. doi:10.1017/S0950268807008667

31. **Coutinho FAB, et al.** Threshold conditions for an non-autonomous epidemic system describing the population dynamics of dengue. *Bulletin of Mathematical Biology* 2006; **68**: 2263–2282.

32. **Luz PM, et al.** Uncertainties regarding dengue modeling in Rio de Janeiro, Brazil. *Memórias do Instituto Oswaldo Cruz* 2003; **98**: 871–878.

33. **Massad E, et al.** Dengue and the risk of urban Yellow Fever reintroduction in São Paulo, Brazil. *Revista de Saúde Pública* 2003; **37**: 477–484.

34. **Massad E, et al.** The risk of Yellow Fever in a dengue infested area. *Transactions of the Royal Society of Tropical Medicine*, 2001; **95**: 370–374.

35. **Marques CA, Forattini OP, Massad E.** The basic reproduction number for dengue fever in São Paulo state, Brazil: 1990–1991 epidemics. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 1994; **88**: 58–59.

36. **Molineaux L.** The epidemiology of human malaria as an explanation of its distribution, including some implications for its control. In: Wernsdorfer WH, McGregor I, eds. *Malaria*. Edinburgh: Churchill Livingstone, 1988.

37. **WHO.** Control of Chagas Disease. WHO Technical Report Series 811. Geneva: World Health Organization, 1991.

38. **Dias JCP, Silveira AC, Schofield CJ.** The impact of Chagas disease control in Latin América – a review. *Memórias do Instituto Oswaldo Cruz* 2002; **97**: 603–612.

39. **Geigy E, Herbig K.** Erreger um Ubertrager tropischer Krankheiten, 1955. Cited in Rey L. *Parasitologia*, 3rd edn, Rio de Janeiro: Guanabara Koogan, 2001.

40. **Silveira AC.** Current situation with Chagas disease vector control in the Americas. *Cadernos de Saúde Pública* 2000; **16**: 35–42.

41. **Busvine JR, Barnes S.** Observations on mortality among insects exposed to insecticidal films. *Bulletin of Entomological Research* 1947; **38**: 80–81.

42. **Dias E, Pellegrino J.** Some assays with 'Gamexanne' in the fight against the transmissors of Chagas' disease [in Portuguese]. *Brazil Médico* 1948; **62**: 185–190.

43. **Schmunis GA.** American trypanosomiasis and its impact on Public Health in the Americas. In: Brener Z, Andrade ZA, Barral-Neto M, eds. *Trypanosoma cruzi e Doença de Chagas*. Rio de Janeiro: Guanabara Koogan, 1999.

44. **Wendell S.** Doença de Chagas transfusional. In: Dias JCP, Coura JR, eds. *Clínica e terapêutica da Doença de Chagas: uma Abordagem Prática para o Clínico Geral*. Rio de Janeiro: Fiocruz, 1997.

45. **Dias JCP, Schofield CJ.** The control of transfusional transmission of Chagas' disease in the South Cone initiative [in Portuguese]. *Revista da Sociedade Brasileira de Medicina Tropical* 1998; **31**: 373–383.

46. **Massad, E.** The basic reproduction ratio of HIV among intravenous drug users. *Mathematical Bioscience* 1994; **123**: 227–247.

47. **Bittencourt AL.** Vertical transmission in Chagas' disease [in Portuguese]. *Revista de Patologia Tropical* 2000; **29** (Suppl.): 101–115.

48. **Mortara G.** Studies on the use of demographic census for reconstitution of birth statistics of Brazilian population [in Portuguese]. *Revista Brasileira de Estatística* 1941; **3**: 41–43.

49. **Reis EJ.** A Economia do Brasil no Século XX, 2004 (http://www.nemesis.org.br/erj002.pdf). Accessed 12 March 2007.

50. **Romaña C, Abalos JW.** Action of 'Gammexane' on triatomidea. Domiciliary 'Control'. *Anals del Instituto de Medicina Regional, Tucuman* 1948; **2**: 95–106.

51. **Vinhaes MC, Dias JCP.** Chagas' Disease in Brazil [in Portuguese]. *Cadernos de Saúde Pública* 2000; **16** (Suppl. 2): 7–12.

52. **Organización Panamericana de la Salud.** Manual de Procedimientos de control de calidad para los laboratórios de serologia de los bancos de sangre. PAHO/HPC/HCT 94.21. Washington, 1994.

53. **Informe Nacional sobre la Enfermedad de Chagas en Uruguay.** Apresentado à Comissão Intergovernamental de Avaliação. Mimeo, 1997, 17 pp.

54. **Souza HM, Ramirez LE, Bordin JO.** Doença de Chagas Transfusional: medidas de controle. In: Dias JCP, Coura JR, eds. *Clínica e terapêutica da Doença de Chagas: uma Abordagem Prática para o Clínico Geral.* Rio de Janeiro: Fiocruz, 1997.

55. **Dias JCP.** Mecanismos de transmissão. In: Brener Z, Andrade ZA, eds. *Trypanosoma cruzi e doença de Chagas.* Rio de Janeiro: Guanabara Koogan Editora, 1979.

56. **Schijman AG.** Congenital Chagas Disease. *Perspectives in Medical Virology* 2006; **13**: 223–258.

57. **Gorla DE.** Environmental variables recorded by remote sensors as indicators of geographical distribution of *Triatoma infestans. Ecologia Austral* 2002; **12**: 117–127.

58. **Murray CJL, Lopez AD.** *The Global Burden of Disease.* Harvard: Harvard University Press, 1996.

59. **World Bank.** *World Development Report 1993: Investing in Health.* New York: Oxford University Press, 1993.

60. **Mathers CD, Lopez A, Murray C.** The burden of disease and mortality by condition: data, methods, and results for the year 2001. In: Lopez A, Mathers C, Ezzati M, Jamison D, Murray C, eds. *Global Burden of Disease and Risk Factor.* New York: Oxford University Press, 2006.

61. **Dias JC.** Control of Chagas' Disease in Brazil. *Parasitology Today* 1987; **3**: 336–341.

62. **Schofield CJ, Dias JC.** A cost-benefit analysis of Chagas' Disease control. *Memorias do Instituto Oswaldo Cruz* 1991; **86**: 285–295.

63. **Dias JCP.** Doença de Chagas em Bambuí, Minas Gerais, Brasil. Estudo Clínico-Epidemiológico a Partir da Fase Aguda entre 1940 e 1982 (Thesis). Universidade Federal de Minas Gerais, Belo Horizonte, 1982.

64. **Souza AG, et al.** Consolidation of the control of Chagas disease vectors in the State of São Paulo. *Memórias do Instituto Oswaldo Cruz* 1984; **79** (Suppl.): 125–132.

65. **Camargo M, et al.** Seroprevalence survey of chagasic infection in Brazil 1975/80 [in Portuguese]. *Revista do Instituto de Medicina Tropical de São Paulo* 1984; **26**: 192–204.

66. **WHO.** Chagas disease, interruption of transmission in Brazil. *Weekly Epidemiologic Records* 2000; **19**: 153–155.

67. **Dias E.** Effects of superinfection on the evolution of chagasic chronic cardiopathy [in Portuguese]. *Revista Goiana de Medicina* 1962; **9** (Suppl.): 233–239.

68. **Macedo VO.** Influence of exposition to reinfection on the evolution of Chagas' disease. A cohort study of 5 years. *Revista de Patologia Tropical* 1976; **5**: 33–115.

69. **Moraes-Souza H.** Transmissão transfusional da doença de Chagas. *Revista de Patologia Tropical* 2000; **29** (Suppl.): 91–100.

70. **Dias JCP, Coura JR.** Epidemiologia. In: Dias JCP, Coura JR, eds. *Clínica e terapêutica da Doença de Chagas: uma Abordagem Prática para o Clínico Geral.* Rio de Janeiro: Fiocruz, 1997.

71. **WHO.** Department of Measurement and Health Information (http://www.who.int/healthinfo/statistics/bodgbddeathdalyestimates.xls). Accessed 14 March 2007.

72. (http://www.ibge.gov.br/home/estatistica/populacao/tabuadevida/2005/ambossexos.pdf). Accessed 14 March 2007.

73. **Smith D, Keyfitz N.** *Mathematical Demography.* Berlin: Springer-Verlag, 1977.

74. **Massad E, et al.** Forecasting versus projection models in epidemiology: the case of the SARS epidemics. *Medical Hypotheses* 2005; **65**: 17–22.

75. **Ministério do Planejamento, Orçamento e Gestão** (http://www.ibge.gov.br/home/estatistica/populacao/tendencia_demografica/tabela01.shtm). Accessed 14 March 2007.

76. (http://www.ibge.gov.br/home/estatistica/populacao/perfildamulher/perfilmulheres.pdf). Accessed 14 March 2007.

77. **Schofield CJ, Dias JCP.** The Southern Cone Initiative against Chagas disease. *Advances in Parasitology* 1999; **42**: 1–27.

78. **Dias JCP.** Chagas disease control and the natural history of human Chagas disease: a possible interaction? *Memórias do Instituto Oswaldo Cruz* 2000; **95** (Suppl. 11): 14–20.

79. **Vinhaes MC.** The situation of Southern Cone Initiative. XI Meeting of the Intergovernmental Commission of the Southern Cone Initiative for the elimination of *Triatoma infestans* and the control of transfusion transmission of Chagas disease. Asunción, Paraguay, 2002.

80. **Coura JR, et al.** Emerging Chagas disease in Amazonian Brazil. *Trends in Parasitology* 2002; **18**: 171–176.

81. **El'sgol'ts EL.** *Introduction to the Theory of Differential Equations with Deviating Arguments.* San Francisco: Holden-Day Inc., 1966.